Lattice Capital Management LLC Takes Position in Insmed Incorporated (NASDAQ:INSM)

Lattice Capital Management LLC purchased a new position in Insmed Incorporated (NASDAQ:INSM) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 3,700 shares of the biopharmaceutical company’s stock, valued at approximately $255,000. Insmed makes up about 0.2% of Lattice Capital Management LLC’s portfolio, making the stock its 26th biggest holding.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. V Square Quantitative Management LLC increased its holdings in Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 248 shares during the last quarter. Spire Wealth Management acquired a new stake in shares of Insmed during the fourth quarter worth approximately $47,000. Venturi Wealth Management LLC bought a new stake in shares of Insmed in the fourth quarter worth $86,000. Blue Trust Inc. raised its holdings in Insmed by 2,348.8% in the third quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock valued at $131,000 after acquiring an additional 1,879 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in Insmed in the third quarter valued at $133,000.

Wall Street Analysts Forecast Growth

INSM has been the subject of several research analyst reports. Truist Financial boosted their target price on shares of Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a research report on Friday. Morgan Stanley boosted their price objective on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Stifel Nicolaus reduced their target price on Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a report on Friday. JPMorgan Chase & Co. lifted their target price on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. Finally, Wells Fargo & Company upped their price target on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Insmed currently has an average rating of “Moderate Buy” and an average price target of $91.00.

Insmed Stock Down 3.0 %

Insmed stock opened at $81.06 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a one year low of $21.92 and a one year high of $84.91. The company has a 50-day simple moving average of $74.29 and a 200-day simple moving average of $73.59. The firm has a market capitalization of $14.50 billion, a P/E ratio of -14.61 and a beta of 1.11.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The business had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. As a group, equities analysts expect that Insmed Incorporated will post -5.42 earnings per share for the current year.

Insider Activity at Insmed

In other Insmed news, CEO William Lewis sold 2,978 shares of the business’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $63.36, for a total transaction of $188,686.08. Following the sale, the chief executive officer now directly owns 392,589 shares in the company, valued at approximately $24,874,439.04. The trade was a 0.75 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Sara Bonstein sold 18,322 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total transaction of $1,471,439.82. Following the completion of the transaction, the chief financial officer now owns 118,863 shares of the company’s stock, valued at $9,545,887.53. This trade represents a 13.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 532,207 shares of company stock worth $41,400,465 in the last three months. 4.60% of the stock is owned by company insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.